TABLE 1.
Demographics of Entire Cohort
| Cohort Total (n = 154) | Cohort AXLlow (n = 70) | Cohort AXLhigh (n = 80) | Cohort GAS‐6low (n = 99) | Cohort GAS‐6high (n = 44) | |||
|---|---|---|---|---|---|---|---|
| n (%) – Median [Range] | |||||||
| Age (years) | 64.2 (22.16‐89.31) | 61.7 (31.7‐89.3) | 65.2 (22.2‐86.1) | [0.154] | 64.1 (22.16‐89.31) | 65.2 (35.61‐84.68) | [0.112] |
| Sex | |||||||
| Male | 105 (68.2) | 43 (61.4) | 60 (75.0) | [0.074] | 70 (70.7) | 32 (72.7) | [0.805] |
| Female | 49 (31.8) | 27 (38.6) | 20 (25.0) | [0.074] | 29 (29.3) | 12 (27.3) | [0.805] |
| Neoplastic entity | |||||||
| mCRC | 62 (40.3) | 49 (70.0) | 13 (16.2) | <0.005 | 57 (57.6) | 5 (11.4) | <0.005 |
| HCC | 50 (32.5) | 4 (5.7) | 44 (55.0) | <0.005 | 20 (20.2) | 28 (63.3) | <0.005 |
| CCC | 25 (16.2) | 7 (10.0) | 16 (20.0) | [0.09] | 12 (12.1) | 10 (22.7) | [0.105] |
| Non‐neoplastic | 12 (7.8) | 8 (11.4) | 4 (5.0) | [0.148] | 7 (7.1) | 0 (0.0) | [0.1] |
| Other | 5 (3.2) | 2 (2.9) | 3 (3.8) | [1.0] | 3 (3.0) | 1 (2.3) | [0.8] |
| Resection extent | |||||||
| Major | 98 (63.6) | 46 (65.7) | 49 (61.2) | [0.571] | 64 (64.6) | 28 (63.6) | [0.907] |
| Minor | 56 (36.4) | 24 (34.3) | 31 (38.8) | [0.571] | 35 (35.4) | 16 (36.4) | [0.907] |
| Outcome | |||||||
| Postoperative LD—yes | 18 (11.7) | 1 (1.7) | 15 (21.7) | <0.005 | 4 (4.8) | 12 (30.8) | <0.005 |
| Morbidity—yes | 77 (50.0) | 26 (37.1) | 47 (58.8) | [0.008] | 36 (36.4) | 33 (75.0) | <0.005 |
| Severe morbidity—yes | 40 (26.0) | 13 (18.6) | 25 (31.3) | [0.075] | 15 (15.2) | 21 (47.7) | <0.005 |
| 90‐day mortality—yes | 5 (3.2) | 0 (0.0) | 4 (5.3) | [0.123] | 0 (0.0) | 4 (9.8) | <0.005 |
| ICU days | 1.0 (0‐26) | 1.0 (0‐5) | 1.0 (0‐26) | [0.123] | 1.0 (0‐10) | 2.0 (0‐26) | [0.014] |
| Hospitalization days | 8.0 (3‐117) | 8.0 (4‐61) | 10.0 (3‐117) | [0.53] | 8.0 (3‐61) | 12.5 (4‐117) | <0.005 |
| Liver histology | |||||||
| Fibrosis—yes | 112 (72.7) | 46 (73.0) | 63 (81.8) | [0.212] | 71 (74.7) | 34 (82.9) | [0.296] |
| Grade 0‐II | 77 (75.6) | 57 (90.5) | 51 (66.2) | <0.005 | 82 (86.3) | 23 (56.1) | <0.005 |
| Grade III‐IV | 35 (24.5) | 6 (9.5) | 26 (33.8) | <0.005 | 13 (13.7) | 18 (43.9) | <0.005 |
| NASH—yes | 52 (33.8) | 26 (49.1) | 26 (40.0) | [0.324] | 38 (52.1) | 13 (31.7) | [0.036] |
| CASH—yes | 29 (18.8) | 20 (40.8) | 9 (15.5) | <0.005 | 25 (36.8) | 3 (8.3) | <0.005 |
| SOS—yes | 13 (8.4) | 10 (16.4) | 3 (4.3) | [0.021] | 13 (14.6) | 0 (0.0) | [0.009] |
| Steatosis (%) | 10.0 (0.0‐100.0) | 5.0 (0.0‐100.0) | 10.0 (0.0‐80.0) | [0.62] | 7.5 (0.0‐85) | 12.5 (0.0‐100.0) | [0.88] |
| Preoperative parameters | |||||||
| PT (%) | 101.0 (40.0‐150.0) | 103.0 (45.0‐150.0) | 97.0 (40.0‐150.0) | [0.071] | 103.0 (45.0‐150.0) | 93.0 (40.0‐150.0) | <0.005 |
| ALP (U/L) | 90.0 (38.0‐707.0) | 90.0 (38.0‐418.0) | 90.5 (42.0‐423.0) | [0.32] | 85.0 (38.0‐418.0) | 104.0 (48.0‐423.0) | <0.005 |
| GGT (U/L) | 68.0 (11.0‐1576.0) | 48.5 (11.0‐505.0) | 92.0 (13.0‐1335.0) | <0.005 | 50.0 (11.0‐710.0) | 157.0 (13.0‐1,335.0) | <0.005 |
| AST (U/L) | 31.0 (17.0‐224.0) | 29.0 (17.0‐71.0) | 34.0 (17.0‐224.0) | [0.024] | 28.0 (17.0‐113.0) | 52.0 (21.0‐224.0) | <0.005 |
| ALT (U/L) | 31.0 (7.0‐372.0) | 26.0 (7.0‐81.0) | 35.0 (8.0‐372.0) | [0.037] | 25.0 (7.0‐123.0) | 46.5 (8.0‐372.0) | <0.005 |
| Albumin (g/L) | 42.0 (30.2‐50.0) | 42.75 (34.0‐50.0) | 42.0 (30.2‐47.6) | [0.031] | 42.0 (34.0‐50.0) | 40.1 (30.2‐47.6) | [0.018] |
| Bilirubin (mg/dL) | 0.6 (0.1‐6.64) | 0.52 (0.0‐2.87) | 0.66 (0.0‐6.64) | <0.005 | 0.55 (0.0‐3.17) | 0.81 (0.0‐6.64) | [0.025 |
Abbreviations: 95% CI, 95% confidence interval; OR, odds ratio; SB, serum bilirubin.mCRC, metastatic colorectal cancer; HCC, hepatocellular cancer; CCC, cholangiocellular cancer; ICU, intensive care unit; NASH, non‐alcoholic steatohepatitis; CASH, chemotherapy associated steatohepatitis; SOS, sinusoidal obstruction syndrome; PT, prothrombin time; ALP, alkaline phosphatase; GGT, gamma‐glutamyl transpeptidase; AST, aspartate aminotransferase; ALT, alanine aminotransferasase.